|
|
 |
| Assist in defining and prioritizing the national research agenda for particular cancer sites, including breast, proStart, and lung by: identifying new or unmet scientific opportunities; reviewing an NCI analysis of its current research program; and, using the ongoing activities as a baseline, providing expert opinions on how to address the opportunities and hasten progress against the disease. |
|
 GYNECOLOGIC CANCER; Final Report November 2001
CO-CHAIRS: William Hoskins, M.D.; Nicole Urban, Sc.D.
EXECUTIVE DIRECTOR: Edward C. Trimble, M.D., M.P.H. |
|
LEUKEMIA, LYMPHOMA, and MYELOMA; Final Report May 2001
CO-CHAIRS: Kenneth C. Anderson, M.D.; Bart Barlogie M.D., Ph.D.; Clara Bloomfield, M.D.
EXECUTIVE DIRECTOR: Wyndham Wilson, M.D., Ph.D |
|
PANCREATIC CANCER
CO-CHAIRS: Scott Kern, M.D. and Margaret Tempero, M.D.
EXECUTIVE DIRECTOR: Barbara Conley, M.D. |
|
BRAIN TUMOR; Final Report NOvember 2000
CO-CHAIRS: David N. Louis M.D. and Jerome B. Posner M.D.
EXECUTIVE DIRECTOR: Thomas Jacobs, Ph.D. |
|
COLORECTAL CANCER; Final Report April 2000
CO-CHAIRS: Bernard Levin, M.D. and Raymond DuBois M.D., Ph.D..
EXECUTIVE DIRECTOR: Barbara Conley, M.D |
|
PROSTATE CANCER; Final Report August 1998
CO-CHAIRS: Peter Scardino, M.D. and Don Tindall, Ph.D.
EXECUTIVE DIRECTOR: Andrew Chiarodo, M.D. |
|
LUNG CANCER; Final Report August 1998
CO-CHAIRS: Margaret R. Spitz, M.D., MPH; John C. Ruckdeschel, M.D.
EXECUTIVE DIRECTOR: Scott Saxman, M.D
|
|
